MARKET

NDRA

NDRA

ENDRA Life
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.690
+0.360
+15.45%
After Hours: 2.820 +0.13 +4.83% 19:59 01/25 EST
OPEN
2.810
PREV CLOSE
2.330
HIGH
2.850
LOW
2.410
VOLUME
7.26M
TURNOVER
--
52 WEEK HIGH
2.850
52 WEEK LOW
0.5990
MARKET CAP
90.50M
P/E (TTM)
-1.4889
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Thinking about buying stock in Palatin Technologies, Motus GI Holdings, Tellurian, OncoCyte, or Endra Life Sciences?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTN, MOTS, TELL, OCX, and NDRA.
PR Newswire - PRF · 4d ago
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 4d ago
Photoacoustic Imaging Market 2021 Research Report by Manufacturers, Regions, Size, Share, Type and Application, Covid-19 Impact, Status and Outlook to 2025
Jan 21, 2021 (The Expresswire) -- Global "Photoacoustic Imaging Market" 2021 Research Report provides key analysis on the market status of the Photoacoustic...
The Express Wire · 4d ago
Thinking about buying stock in Dare Bioscience, Endra Life Sciences, Lineage Cell Therapeutics, Inuvo Inc, or eMagin Corp?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, NDRA, LCTX, INUV, and EMAN.
PR Newswire - PRF · 5d ago
TRXC, GEVO, FVRR and LITE among midday movers
Gainers: Aclaris Therapeutics (ACRS) +184%.Gritstone Oncology (GRTS) +111%.Gevo (GEVO) +76%.Senseonics (SENS) +72%.TransEnterix (TRXC) +62%.Dare Bioscience (DARE) +57%.ENDRA Life Sciences (NDRA) +41%.Pennsylvania Real Estate Investment Trust (PEI) +41%.Ten...
Seekingalpha · 6d ago
Thinking about buying stock in DBV Technologies, Endra Life Sciences, Precision BioSciences, Sorrento Therapeutics, or Aldeyra Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DBVT, NDRA, DTIL, SRNE, and ALDX.
PR Newswire - PRF · 6d ago
GME, LAC, AMC and COHR among premarket gainers
Tenax Therapeutics, Inc. (TENX) +70% after announcing acquisition of PH Precision Med.Aclaris Therapeutics (ACRS) +66% on positive data from mid-stage rheumatoid arthritis.Minerva Neurosciences (NERV) +42% on announcing sale of Seltorexant Royalty for up
Seekingalpha · 6d ago
ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology
United States Patent and Trademark Office issued U.S. Patent 10888898 entitled "Shielded Ultrasound Transducer and Imaging System Employing the Same" to ENDRA Life Sciences (NDRA).This is the 13th U.S. patent issued to ENDRA for its
Seekingalpha · 01/13 21:54
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NDRA. Analyze the recent business situations of ENDRA Life through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NDRA stock price target is 5.17 with a high estimate of 6.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 23
Institutional Holdings: 1.02M
% Owned: 3.03%
Shares Outstanding: 33.64M
TypeInstitutionsShares
Increased
8
68.86K
New
3
151.15K
Decreased
1
16.30K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.02%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Chief Executive Officer/Director
Francois Michelon
Chief Financial Officer
David Wells
Chief Technology Officer
Michael Thornton
Other
Renaud Maloberti
Independent Director
Louis Basenese
Independent Director
Anthony DiGiandomenico
Independent Director
Sanjiv Gambhir
Independent Director
Michael Harsh
Independent Director
Alexander Tokman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NDRA
ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The Company's Nexus 128 system combines light-based thermoacoustics and ultrasound, to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company is involved in developing Thermo Acoustic Enhanced Ultrasound (TAEUS) for incorporation into new ultrasound systems. The TAEUS platform has capabilities and potential clinical applications, such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature, in real time; enabling ultrasound to view blood vessels from any angle, using only a saline solution contrasting agent, unlike Doppler ultrasound which requires precise viewing angles, and enabling ultrasound to image blood flow at the capillary level in a region, organ or tissue.
More

Webull offers kinds of ENDRA Life Sciences Inc stock information, including NASDAQ:NDRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NDRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NDRA stock methods without spending real money on the virtual paper trading platform.